WILEX and RedHill Biopharma enter into an exclusive license agreement for MESUPRON®
- WILEX will receive an upfront payment of USD 1 million and double digit royalties of up to 30% on net revenues
- RedHill will be responsible for all development and commercialization costs for MESUPRON®
- RedHill receives exclusive development and commercialization rights outside of China, Hong Kong, Taiwan and Macao
| PDF Download
Munich, Germany / Tel-Aviv, Israel, June 30, 2014. WILEX AG (ISIN DE0006614720/ WL6 / FSE) and RedHill Biopharma Ltd. (NASDAQ: RDHL; TASE: RDHL), an Israeli biopharmaceutical company focused on late clinical-stage drugs for inflammatory and gastrointestinal diseases, including cancer, today announced that they have signed an exclusive license agreement for the oncology drug candidate MESUPRON®. The small molecule is a proprietary, first-in-class urokinase-type plasminogen activator (uPA) inhibitor administered by oral capsule. Wilex has completed several clinical studies with MESUPRON® in different indications, including two Phase II proof of concept studies for pancreatic cancer and metastatic breast cancer.
Under the terms of the agreement, RedHill acquired the exclusive development and commercialization rights to MESUPRON® outside China, Hong Kong, Taiwan and Macao for all indications. RedHill will pay Wilex an upfront payment of USD 1 million and potential tiered royalties on net revenues, ranging from mid-teens up to 30%. RedHill will be responsible for development, regulatory and commercialization of MESUPRON®.
Dror Ben-Asher, RedHill’s CEO, said: “The acquisition of MESUPRON® reflects our commitment to patients suffering from gastrointestinal and inflammatory diseases, including related cancers such as pancreatic cancer, gastric cancer and colorectal cancer. It adds to RedHill’s pipeline of six late clinical-stage drug candidates and fits well with our risk-mitigating business model. MESUPRON® is a unique, non-cytotoxic approach targeting oncology indications where there is a very strong demand for better therapeutic options. Thanks to the development work conducted by Wilex, MESUPRON® is supported by extensive pre-clinical and clinical data, and we believe in its potential to become an important treatment option for cancer patients. Our experienced development team is enthusiastic to advance this important new drug. We look forward to collaborating with our new partner Wilex and would like to thank them for entrusting us with the development and commercialization of MESUPRON®.”
Dr. Paul Bevan, Head of R&D of WILEX, commented: “We are very delighted about today’s signing of the second license agreement for MESUPRON® within the last three months. With RedHill, we have now concluded the final step for the global out-licensing of our drug candidate MESUPRON®. RedHill is an experienced and knowledgeable partner and highly committed to further progressing MESUPRON® towards regulatory approval and commercialization.”
MESUPRON® (INN: Upamostat) is a proprietary, first-in-class urokinase-type plasminogen activator (uPA) inhibitor administered by oral capsule. The uPA system has been shown to play a key role in tumor cell growth, invasion and the metastasis process. High uPA levels are associated with poor prognosis in various solid tumor cancers, such as pancreatic, gastric, breast and prostate cancers. MESUPRON® presents a promising new non-cytotoxic approach to cancer therapy with several potential mechanisms of action to inhibit both tumor metastasis and growth. MESUPRON® has completed several Phase I studies and two Phase II proof of concept studies, the first Phase II study in locally advanced non-metastatic pancreatic cancer and the second in metastatic breast cancer, which have established its safety and tolerability profile. The Phase II studies with MESUPRON® in both indications suggested activity as measured by both tumor response rate and overall survival of patients when administered in combination with first-line chemotherapeutic agents.
WILEX AG is a biopharmaceutical company based in Munich, Germany. Focused on oncology, the Company develops diagnostic and therapeutic product candidates based on antibodies and small molecules, which are available for out-licensing. The subsidiary Heidelberg Pharma GmbH offers preclinical contract research services and an antibody drug conjugate (ADC) technology platform. Our customers and partners include leading international pharmaceutical companies. More information is available at www.wilex.com.
About RedHill Biopharma Ltd.
RedHill Biopharma Ltd. (NASDAQ: RDHL) (TASE: RDHL) is an emerging Israeli biopharmaceutical company focused primarily on the development and acquisition of late clinical-stage, proprietary drugs for the treatment of inflammatory and gastrointestinal diseases, including cancer. RedHill’s current pipeline of proprietary products includes: (i) RHB-104 – an oral combination therapy for the treatment of Crohn’s disease, with an ongoing Phase III study; (ii) RHB-105 – an oral combination therapy for Helicobacter pylori infection, with an ongoing Phase III study; (iii) RHB-106 – an encapsulated formulation for bowel preparation licensed to Salix Pharmaceuticals, Ltd.; (iv) MESUPRON® – a Phase II uPA inhibitor, administered by oral capsule, targeting gastrointestinal and other solid tumor cancers; (v) RHB-102 – a once-daily oral pill formulation of ondansetron for the prevention of nausea and vomiting, in advanced development stages for multiple indications, including a European marketing application for chemotherapy and radiotherapy-induced nausea and vomiting planned for the third quarter of 2014 and a Phase III study for an undisclosed indication planned to commence in 2014, (vi) RHB-103 – an oral thin film formulation of rizatriptan for acute migraines with an U.S. NDA under FDA review and a European marketing application planned for the third quarter of 2014; and (vii) RHB-101 – a once-daily oral pill formulation of the cardio drug carvedilol. For more information please visit www.redhillbio.com.
Tel.: +49 (0)89-41 31 38-29
Grillparzerstr. 10, 81675 Munich, Germany
MC Services AG
Katja Arnold (CIRO)
Tel.: +49-89-210 228-40
Mobil: +49 160 9360 3022
PR contact (U.S.)
This communication contains certain forward-looking statements relating to the Company’s business, which can be identified by the use of forward-looking terminology such as “estimates”, “believes”, “expects”, “may”, “will”, “should”, “future”, “potential” or similar expressions or by a general discussion of the Company’s strategy, plans or intentions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results of operations, financial position, earnings, achievements, or industry results, to be materially different from any future results, earnings or achievements expressed or implied by such forward-looking statements. Given these uncertainties, prospective investors and partners are cautioned not to place undue reliance on such forward-looking statements. We disclaim any obligation to update any such forward-looking statements to reflect future events or developments.